Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT819 in B-cell Mediated Autoimmune Disease
NCT06308978Phase 1Recruiting
- Sponsor
- Fate Therapeutics
- Start
- Mar 2024
- Primary completion
- Sep 2027
- Modality
- CAR-T Cells, Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 4
01
Overview
Phase 1, open-label trial of FT819 in systemic lupus erythematosus (SLE), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), idiopathic inflammatory myopathies (IIM) and 2 more (5 arms), sponsored by Fate Therapeutics. Primary endpoints: Treatment-emergent adverse events at 2 years, Serious treatment-emergent adverse events at 2 years and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
FT819
03
Conditions
systemic lupus erythematosus (SLE)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathies (IIM)systemic sclerosis (SSc)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06308978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308978.